Form 4: Orchestra BioMed Director Buys 5,760 Shares

Orchestra BioMed Holdings, Inc. Director Eric S. Fain acquired 5,760 shares of common stock at a weighted average price of $2.61.

Summary

• Eric S. Fain, a Director of Orchestra BioMed Holdings, Inc. (OBIO), purchased 5,760 shares of the company's common stock.
• The transaction occurred on August 25, 2025, and was made pursuant to a Rule 10b5-1(c) plan.
• The shares were acquired at a weighted average price of $2.61 per share, with individual transaction prices ranging from $2.60 to $2.61.
• Following this transaction, Eric S. Fain beneficially owns 71,709 shares of common stock indirectly through the Fain Living Trust.

Sentiment

Score: 7

Explanation: Director Eric S. Fain's purchase of company stock indicates confidence in Orchestra BioMed's future prospects, which is generally viewed positively by the market.

Positives

• The purchase of company stock by a director, Eric S. Fain, indicates confidence in the company's current valuation and future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy.

Future Outlook

This filing is a report of an insider transaction and does not contain explicit forward-looking statements or guidance from the company.

Industry Context

Insider buying, such as this director's purchase, can be a positive signal within the biomedical industry, suggesting that those with intimate knowledge of the company believe in its future potential, especially in a sector often characterized by high R&D costs and long development cycles.

Related Party Transactions

• Director Eric S. Fain, a related party, purchased 5,760 shares of common stock from the issuer.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.

Key Dates

Recommendation

The director's purchase of additional shares signals confidence in the company's valuation and future, which could support a 'hold' recommendation for existing investors and encourage further due diligence for potential new investors. While positive, a single insider transaction of this size typically warrants a 'hold' rather than a 'strong buy' without additional corroborating information.

Keywords

Orchestra BioMed, OBIO, Insider Trading, Stock Purchase, Director, Eric S. Fain, Form 4, Biomedical